Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer

Phase 2Enrolling By InvitationNCT05170919

Englewood Hospital and Medical Center170 enrolled

Overview

To determine whether olanzapine or mirtazapine is more effective in preventing weight loss and appetite loss in cancer patients.

Olanzapine and Mirtazapine have been used in the past few years to attempt to prevent weight and appetite loss in cancer patients. Both have mixed study results and none of the previous studies are of high enough quality to make clinical recommendations. With limited options available, palliative and oncology providers turn to these medications with little evidence. There are no formal studies comparing the two to determine if one is superior to the other, so choices are often made based purely on provider preference. We aim to conduct a study to determine if one of the drugs outperforms the other to guide our standard practice at Englewood Health. This study is being conducted to determine whether olanzapine or mirtazapine is more effective in preventing weight loss and appetite loss in cancer patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

170

Conditions

Anorexia Nervosa with Significantly Low Body Weight

Interventions

MirtazapineDRUG

Patients will be prescribed a dosage of 15 mg per day. Dose will not be escalated.

OlanzapineDRUG

the participant will be prescribed a dosage of 2.5mg per day if \> 65 yrs. and 5 mg/per day if \<65 yrs. per day. Per physician discretion, participants are allowed a dose escalation of a maximum of 10mg.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * • 18 years of age or older * Able to provide informed consent * Pathologically and/or clinically confirmed diagnosis of advanced cancer * At any point of treatment with standard chemotherapy\* o Scheduled to start, have discontinued or completed, or currently receiving * Greater than or equal to 5% unintentional weight loss over the previous 3-6 months, not explained by simple starvation o Simple starvation is considered to be excluded when weight loss is not ameliorated by standard nutritional counseling and oral supplementation over a 2-week period). * Life expectancy of at least 4 months * Able to communicate well and comply with study requirements, including by phone and written logs * Patients on Dexamethasone will be allowed Exclusion Criteria: * • Abnormal liver function defined as \> twice upper limit of normal * Elevated QTc o EKG performed within 1 year of enrollment will be accepted * Total parental nutrition (TPN) or enteral feeds (PEG/PEJ) for \>70% of their primary source of daily calorie intake * Taking Marinol within 2 week of enrollment onto study

Locations (1)

Englewood Health

Englewood, New Jersey, United States

Outcomes

Primary Outcomes

Weight

Patients will have their weight measured every month. A ratio of 5% weight gain or weight stabilization over time will be used to determine if the medication is making an impact.

Time frame: 6 months

Secondary Outcomes

Quality of Life of patient

Patients will complete a quality of life (QOL) questionnaire provided at each time point. The higher the score, the worse the outcome. Patients will rate their improvement on a scale from 0 to 4.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.